TechInvention Lifecare announces the ground breaking of its state-of-the-art Global Collaborative Centre for Medical Countermeasures

This facility will serve the needs of both public and private organizations, such as academic institutes, start-ups, MSMEs, and R&D organizations, to provide a comprehensive ecosystem, facilitating the transition from R&D to GMP-scale production for pre-clinical/clinical batches with required regulatory approvals.

GCMC is a unique eco-friendly centre to cater to crucial medical countermeasures—the entire cycle of vaccine development, from strain to supply, biotherapeutics and diagnostics for both human and veterinary segments, while ensuring sustainable manufacturing. This initiative aligns with the One Health approach, emphasizing the interconnection between human, animal, and environmental health.

Mr. Syed S. Ahmed, Director and CEO of TechInvention, expressed, “The current challenges posed in biologics equity arise from the disparity in translational research dissemination from the centres of excellence to the regional manufacturing ‘hub and spoke’ model setups. We believe that GCMC would be the needed intervention, strengthening the hubs by providing ‘scaled-up’, regulatory-approved, cost-effective, and free of IP infringement biosolutions sourced from both indigenous research and centres of excellence worldwide”.

About TechInvention Lifecare Pvt. Ltd.

TechInvention Lifecare Pvt. Ltd. distinguishes itself as a unique Indian biotech company, supporting the ‘One Health’ concept by integrating three pivotal interventions: diagnostics, vaccines, and biotherapeutics, catering to both human and veterinary sectors. Its innovation is dedicated to advancing global health through novel solutions. With a focus on research and development, the company is committed to addressing the health challenges that may emerge in the future.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.